Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Plimack, E. R.; Hammers, H. J.; Rini, B. I.; McDermott, D. F.; Redman, B.; Kuzel, T.; Harrison, M. R.; Vaishampayan, U. N.; Drabkin, H. A.; George, S.; Logan, T. F.; Margolin, K. A.; Xu, L. A.; Waxman, I.; Motzer, R. |
| Abstract Title: | Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901024 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.4553 |
| Notes: | Meeting Abstract: 4553 -- Source: Wos |
